Hepalatide
Phase 2Peptide
Hepalatide is one of 64 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Phase 2.
2
Indications
8
Total Trials
2
Active Trials
63
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
676 competitors in Type 2 Diabetes Mellitus
#DrugCompanyPhaseTrials
1Byetta
AstraZenecaPreclinical
Tanzeum
GSKPreclinical
Insulin 320
Novo NordiskPreclinical
NOVOLIN R
Novo NordiskPreclinical
Adenocard
AstellasPreclinical
Dostinex
PfizerPreclinical
Golytely
BayerPreclinical
Cipro
BayerPreclinical
Lantus
SanofiPreclinical
Hepalatide
SShanghai HEP Pharmaceutical Co., Ltd.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Hepatitis5 trials
Type 2 Diabetes Mellitus1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Hepalatide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details